Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

(Family Features) Even though cooler days may seem far off, now is the best time to plan ahead for a healthy winter. One ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease ...

For older adults, this means that RSV isn’t just another respiratory virus, but a disease that can have severe consequences. In Asia, up to 80 per cent of older adults hospitalised with RSV ...